Vertex Pharmaceuticals Inc. Products & Brands

Products

Category

Product

Brand

Description

Gene Editing Therapeutics Market (BIO259A)

CASGEVY

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy. It is indicated for the treatment of patients aged 12 years and older with sickle cell disease (SCD) with recurrent vaso occlusive crises (VOCs) and transfusion-dependent ß-thalassemia (TDT). CASGEVY was first approved in December 2023 for SCD and in January 2024 for TDT.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.